Bacterial challenges and evolving antibacterial drug strategy
Open Access
- 1 January 1992
- journal article
- review article
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 68 (795) , 6-21
- https://doi.org/10.1136/pgmj.68.795.6
Abstract
No abstract availableThis publication has 79 references indexed in Scilit:
- Chemotherapy for infections caused by Haemophilus influenzae: current problems and future prospectsJournal of Antimicrobial Chemotherapy, 1991
- Comparative in vitro and in vivo activity of rifabutin and rifampicin against mycobacterium avium complexTubercle, 1988
- SURGICAL PROPHYLAXIS—THE EMERGING PICTUREThe Lancet, 1988
- Ceftazidime Combined with a Short or Long Course of Amikacin for Empirical Therapy of Gram-Negative Bacteremia in Cancer Patients with GranulocytopeniaNew England Journal of Medicine, 1987
- In vitro activity of new rifamycins aganst rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteriaTubercle, 1987
- In vitro susceptibility to aminoglycoside antibiotics in blood and urine isolates consecutively collected in twenty-nine European laboratoriesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- Imipenem/CilastatinDrugs, 1987
- Prevention of Haemophilus influenzae Type b Infections in Day Care: A Public Health PerspectiveClinical Infectious Diseases, 1986
- Detennlnation of the activity onLegionella of eight macrolides and related agents by comparative testing on three mediaJournal of Antimicrobial Chemotherapy, 1985
- Legionnaires' Disease — The First Thousand DaysNew England Journal of Medicine, 1979